BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 20421155)

  • 1. Whole abdominopelvic radiotherapy using intensity-modulated arc therapy in the palliative treatment of chemotherapy-resistant ovarian cancer with bulky peritoneal disease: a single-institution experience.
    De Meerleer G; Vandecasteele K; Ost P; Delrue L; Denys H; Makar A; Speleers B; Van Belle S; Van den Broecke R; Fonteyne V; De Neve W
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):775-81. PubMed ID: 20421155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole abdominopelvic radiotherapy in the palliative treatment of pseudomyxoma peritonei.
    Berkovic P; van de Voorde L; De Meerleer G; Delrue L; Speleers B; Van Belle S; Vandecasteele K
    Strahlenther Onkol; 2014 Feb; 190(2):223-8. PubMed ID: 24306063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer FIGO stage III: final results of a prospective phase 2 study.
    Arians N; Kieser M; Benner L; Rochet N; Schröder L; Katayama S; Herfarth K; Schubert K; Schneeweiss A; Sohn C; Lindel K; Debus J
    Radiat Oncol; 2019 Oct; 14(1):179. PubMed ID: 31639066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective palliative radiation therapy in advanced and recurrent ovarian carcinoma.
    Tinger A; Waldron T; Peluso N; Katin MJ; Dosoretz DE; Blitzer PH; Rubenstein JH; Garton GR; Nakfoor BA; Patrice SJ; Chuang L; Orr JW
    Int J Radiat Oncol Biol Phys; 2001 Dec; 51(5):1256-63. PubMed ID: 11728685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent ovarian cancer. Effective radiotherapeutic palliation after chemotherapy failure.
    Corn BW; Lanciano RM; Boente M; Hunter WM; Ladazack J; Ozols RF
    Cancer; 1994 Dec; 74(11):2979-83. PubMed ID: 7525039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant Intensity Modulated Whole-Abdominal Radiation Therapy for High-Risk Patients With Ovarian Cancer (International Federation of Gynecology and Obstetrics Stage III): First Results of a Prospective Phase 2 Study.
    Arians N; Kieser M; Benner L; Rochet N; Katayama S; Sterzing F; Herfarth K; Schubert K; Schröder L; Leitzen C; Schneeweiss A; Sohn C; Debus J; Lindel K
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):912-920. PubMed ID: 28870790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study.
    Rochet N; Sterzing F; Jensen AD; Dinkel J; Herfarth KK; Schubert K; Eichbaum MH; Schneeweiss A; Sohn C; Debus J; Harms W
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1382-9. PubMed ID: 19628341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and Predictive Value of the Peritoneal Cancer Index in Primary Advanced Epithelial Ovarian Cancer Patients After Complete Cytoreductive Surgery: Study of Tumor Bank Ovarian Cancer.
    Gasimli K; Braicu EI; Richter R; Chekerov R; Sehouli J
    Ann Surg Oncol; 2015 Aug; 22(8):2729-37. PubMed ID: 25672560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: the Kaohsiung Chang Gung experience.
    Hu CF; Ou YC; Fu HC; Chang Chien CC; Tsai CC; Wu CH; Lin H
    Taiwan J Obstet Gynecol; 2015 Feb; 54(1):43-7. PubMed ID: 25675918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III--the OVAR-IMRT-02 Study.
    Rochet N; Kieser M; Sterzing F; Krause S; Lindel K; Harms W; Eichbaum MH; Schneeweiss A; Sohn C; Debus J
    BMC Cancer; 2011 Jan; 11():41. PubMed ID: 21276234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
    Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
    Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palliative Radiation Therapy for Recurrent Ovarian Cancer: Efficacy and Predictors of Clinical Response.
    Jiang G; Balboni T; Taylor A; Liu J; Lee LJ
    Int J Gynecol Cancer; 2018 Jan; 28(1):43-50. PubMed ID: 29040187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction?
    Perri T; Ben-Baruch G; Kalfon S; Beiner ME; Helpman L; Hogen LB; Shapira-Frommer R; Korach J
    Gynecol Oncol; 2013 Oct; 131(1):27-31. PubMed ID: 23880152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study.
    Friedlander ML; Stockler M; O'Connell R; Voysey M; Oza A; Gillies K; Donovan H; Martyn J; Sjoquist K; Butow P; King MT;
    Int J Gynecol Cancer; 2014 Jun; 24(5):857-64. PubMed ID: 24844219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole abdominopelvic intensity-modulated radiation therapy for peritoneal disseminated rhabdomyosarcoma with three-year follow-up: a case report.
    Kawamura M; Okudaira K; Itoh Y; Kamomae T; Nishikawa E; Muramatsu H; Takahashi Y; Yokota K; Naganawa S
    Radiat Oncol; 2019 Jul; 14(1):127. PubMed ID: 31307511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial.
    Chang JS; Kim SW; Kim YJ; Kim JY; Park SY; Kim JH; Jang TK; Kim YB
    Gynecol Oncol; 2018 Oct; 151(1):39-45. PubMed ID: 30146110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy for isolated recurrent epithelial ovarian cancer: A single institutional experience.
    Komura N; Mabuchi S; Isohashi F; Yokoi E; Shimura K; Matsumoto Y; Kodama M; Tomimatsu T; Ogawa K; Kimura T
    J Obstet Gynaecol Res; 2019 Jun; 45(6):1173-1182. PubMed ID: 30843318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twenty-five year outcome of sequential abdominal radiotherapy and melphalan:implications for future management of epithelial carcinoma of the ovary.
    Dusenbery KE; Bellairs EE; Potish RA; Twiggs LB; Boente MP
    Gynecol Oncol; 2005 Feb; 96(2):307-13. PubMed ID: 15661213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Image-guided intensity-modulated whole abdominal radiation therapy in relapsed epithelial ovarian cancers: a feasibility study.
    Shetty UM; Shankar S; Engineer R; Chopra S; Gupta S; Maheshwari A; Kerkar R; Shrivastava SK
    J Cancer Res Ther; 2013; 9(1):17-21. PubMed ID: 23575068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.